Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

New research suggests that semaglutide, the active ingredient in GLP-1 drugs like Ozempic and Wegovy, might protect against dementia. More than 6 million Americans are diagnosed with dementia each ...

But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that contribute to dementia risk, including obesity, type 2 diabetes ...

Researchers at Case Western Reserve University have discovered that the popular diabetes and weight-loss drug Ozempic may lower a person’s risk of developing dementia.. The active ingredient in ...

The unexpected ways Ozempic-like drugs might fight dementia. They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the ...

Talk about a lucky charm. Drugs like Ozempic — which mimic the appetite-suppressing GLP-1 hormone the body naturally produces after eating — have been shown to spur weight loss as well as ease ...

Ozempic Might Be a Dementia Buster, Too Like semaglutide (Ozempic and Wegovy) and tirzepatide (Zepbound and Mounjaro) before it, MariTide mimics GLP-1, a hormone important to regulating our hunger ...

Should Everyone Be Taking Ozempic? Doctors Say More People Could Benefit. Anti-obesity drugs are showing promise for ever-expanding list of diseases. By . Peter Loftus. Share. Resize. Listen ...